GB876027A - New vaccines and a process for their manufacture - Google Patents
New vaccines and a process for their manufactureInfo
- Publication number
- GB876027A GB876027A GB8863/58A GB886358A GB876027A GB 876027 A GB876027 A GB 876027A GB 8863/58 A GB8863/58 A GB 8863/58A GB 886358 A GB886358 A GB 886358A GB 876027 A GB876027 A GB 876027A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- vaccines
- metal oxide
- antigen
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Depot vaccines comprising an antigen absorbed on a metal oxide are made by mixing (a) an antigen consisting of a virus, a bacterial antigen, a toxin produced by bacteria or an inactivation product of any of these, (b) a finely-divided metal oxide which is non-injurious to human and animal tissue and possesses a molar surface area of about 40,000 to 80,000 square metres, (c) buffering and isotonicizing substances, (d) water, and optionally (e) substances for raising the viscosity of the vaccine for example gelatine. The proportions of the ingredients are so chosen that the mixture contains per ml. about 106 to 109 virus or bacterial particles or the equivalent quantity of toxin or toxoid, and a quantity of metal oxide corresponding to a surface area of about 2 to 20 square metres. The mixture is thoroughly agitated for about 20 to 40 minutes at a temperature of about 0 DEG to 30 DEG C. The vaccines may be cautiously dehydrated, preferably by lyophilization to give stable dry preparations which can be readily reconverted into vaccines by recombination with the previously removal liquid medium and shaking for a short time. Examples given of (a) antigens are: all strains of influenza virus, strains A/Asia/1/57, PR8, B/Berlin/7/57, A1/England/19/55, A1/Dutch/56 being specifically mentioned, mumps virus strain "Enders," poliomyelitis virus, foot and mouth disease virus, viruses of the ECHO group, viruses of the coxsackie group, measles virus; bacterial antigens of B.Salmonella typhi, B.Erysipelas, B.Brucella Abortis Bang., B.Hemophilus Pertusses, B.Tuberculosis; the toxins and toxoids derived from B.Diphtheri Haemopholis, B. Tetani; of (b) metal oxides; those of aluminium, zirconium, magnesium, iron; of (c) additional agents; sodium chloride, primary potassium phosphate, secondary sodium phosphate.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DED25189A DE1041647B (en) | 1957-03-19 | 1957-03-19 | Process for the production of depot vaccines which are in adsorption equilibrium |
Publications (1)
Publication Number | Publication Date |
---|---|
GB876027A true GB876027A (en) | 1961-08-30 |
Family
ID=7038445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8863/58A Expired GB876027A (en) | 1957-03-19 | 1958-03-19 | New vaccines and a process for their manufacture |
Country Status (4)
Country | Link |
---|---|
BE (1) | BE565793A (en) |
DE (1) | DE1041647B (en) |
GB (1) | GB876027A (en) |
SE (1) | SE314164B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3470067A (en) * | 1967-09-19 | 1969-09-30 | Pfizer & Co C | Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes |
EP1361859A1 (en) * | 2001-02-15 | 2003-11-19 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
FR2854803A1 (en) * | 2003-05-16 | 2004-11-19 | Aventis Pasteur | Composition for treating tetanus, diphtheria and poliomyelitis, comprises vaccine antigen and adjuvant comprising iron phosphate |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19511276C2 (en) * | 1995-03-27 | 1999-02-18 | Immuno Ag | Adjuvant based on colloidal iron compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE885466C (en) * | 1951-09-22 | 1953-08-06 | Byk Gulden Lomberg Chem Fab | Process for the preparation of a vaccine against sleeping sickness |
-
0
- BE BE565793D patent/BE565793A/xx unknown
-
1957
- 1957-03-19 DE DED25189A patent/DE1041647B/en active Pending
-
1958
- 1958-03-11 SE SE2370/58A patent/SE314164B/xx unknown
- 1958-03-19 GB GB8863/58A patent/GB876027A/en not_active Expired
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3470067A (en) * | 1967-09-19 | 1969-09-30 | Pfizer & Co C | Concentration and purification of viruses from particulate magnetic iron oxide-virus complexes |
EP1361859A1 (en) * | 2001-02-15 | 2003-11-19 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
EP1361859A4 (en) * | 2001-02-15 | 2009-05-20 | Kos Life Sciences Inc | Modulated release particles for aerosol delivery |
FR2854803A1 (en) * | 2003-05-16 | 2004-11-19 | Aventis Pasteur | Composition for treating tetanus, diphtheria and poliomyelitis, comprises vaccine antigen and adjuvant comprising iron phosphate |
WO2004103408A2 (en) * | 2003-05-16 | 2004-12-02 | Sanofi Pasteur | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
WO2004103408A3 (en) * | 2003-05-16 | 2005-03-17 | Aventis Pasteur | Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
JP2006528958A (en) * | 2003-05-16 | 2006-12-28 | サノフィ・パスツール | Vaccine composition comprising iron phosphate as vaccine adjuvant |
Also Published As
Publication number | Publication date |
---|---|
DE1041647B (en) | 1958-10-23 |
BE565793A (en) | 1900-01-01 |
SE314164B (en) | 1969-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chandran et al. | Development of a recombinant epsilon toxoid vaccine against enterotoxemia and its use as a combination vaccine with live attenuated sheep pox virus against enterotoxemia and sheep pox | |
JPH01230532A (en) | Novel vaccine and its production | |
Jin et al. | Immune responses induced by recombinant Lactobacillus plantarum expressing the spike protein derived from transmissible gastroenteritis virus in piglets | |
Vershilova | The use of live vaccine for vaccination of human beings against brucellosis in the USSR | |
CN1062770C (en) | Vaccine both for hepatitis A and measles and production method therefor | |
Cate et al. | Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence | |
GB1256456A (en) | Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations | |
US3155589A (en) | Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis | |
Spradbrow et al. | Recent isolates of Newcastle disease virus in Australia | |
GB876027A (en) | New vaccines and a process for their manufacture | |
CN103656660B (en) | A kind of animal heat-resisting lyophilized protecting agent of live vaccine, its preparation method and application | |
Meyer et al. | Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffkine and freeze-dried plague vaccine | |
US3178350A (en) | Biologic antigens adjuvanted with a colloidally water-soluble polymer of acrylic acidcrosslinked with polyallyl sucrose or polyallyl pentaerythritol | |
GB1256457A (en) | Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation | |
Eidson et al. | Vaccination of broiler chicks from breeder flocks immunized with a live or inactivated oil emulsion Newcastle disease vaccine | |
GB1461188A (en) | Live influenza virus vaccines and preparation thereof | |
CN100340290C (en) | Induction of mucosal immunity by vaccination via skin nute | |
Weiss | Observations on Bacterium melaninogenicum: Demonstration of Fibrinolysin, Pathogenicity and Serological Types. | |
Myint et al. | Possible method for the production of a Covid-19 vaccine | |
Stashak et al. | The serum antibody response to bacteriophage ΦX174 in germ-free and conventionally reared mice: I. Assay of neutralizing antibody by a 50 per cent neutralization method | |
Schieble et al. | Antigenic variation of rhinovirus type 22 | |
Stalheim | Viable, avirulent Leptospira interrogans serotype pomona vaccine: Preservation in liquid nitrogen | |
Rappaport et al. | Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen | |
RU2204599C1 (en) | Foot-and-mouth virus strain "primorsky-2000" 1734 of type o1 for diagnostic and vaccine preparation preparing | |
Coggins et al. | Serological Comparison with Rabbit Antisera of Hog Cholera Virus and Bovine Virus Diarrhea Virus. |